HomeDatabaseGLP-1 / Metabolic › AOD-9604
GLP-1 / Metabolic

AOD-9604 — Half-Life, Dosing & Protocol Guide

Also known as: HGH Fragment 176-191, Tyr-hGH 177-191

Preclinical · Heffernan et al., Endocrinology 2001 — No human PK study pub
Plasma Half-Life
~0.5h (preclinical estimate only)
Source: Heffernan et al., Endocrinology 2001 — No human PK study published
Route
Subcutaneous injection
Frequency
Once daily (fasted)
Dose Range
250–500mcg SC daily
Category
GLP-1 / Metabolic
⚠ No Published Human Pharmacokinetic Data
Half-life values are based on preclinical (animal) studies or community estimates only.

Pharmacokinetics & Mechanism

AOD-9604 is a synthetic 16-amino-acid C-terminal HGH fragment (residues 177–191) with N-terminal tyrosine substitution. No human pharmacokinetic study has been published; the ~0.5h estimate derives from peptide size and rodent data (Heffernan et al. 2001). It activates β3-adrenergic lipolysis without binding the GH receptor or raising IGF-1. Clinical development was discontinued after Phase IIb failed to demonstrate significant weight loss versus placebo. The FDA has listed AOD-9604 as a bulk drug substance that may not be used in compounded preparations under Sections 503A and 503B.

Track AOD-9604 in Halflife

The Halflife app models your AOD-9604 concentration curve in real time — see exactly when your dose peaks, when it troughs, and how it overlaps with other compounds in your stack. All stored on-device, no account required.

See your AOD-9604 curve live

Real-time pharmacokinetic model · Free iOS app

Download on App Store
See also: Full technical profile → All 45 compounds About the app